Objectives: Raltegravir has been demonstrated to have a favourable impact on several metabolic parameters, including a lack of changes in lipid and glucose concentrations. We aimed to assess the effect on endothelial function of switching from a ritonavir-boosted protease inhibitor (PI/r)-based regimen to raltegravir.
Introduction
Cardiovascular disease risk is increased in HIV-infected patients. Antiretroviral therapy (ART) and, specifically, ritonavir-boosted protease inhibitor (PI/r)-containing regimens have been associated with an augmented risk of myocardial infarction, which was explained at least in part by dyslipidaemia. 1 Raltegravir is the first approved inhibitor of a novel target, the retroviral integrase, and it does not require ritonavir boosting. It has demonstrated a favourable impact on several metabolic parameters in clinical trials, including a lack of changes in lipid and glucose concentrations in naive patients, 2 and a decrease in plasma lipids after switching from PI/r-based regimens. 3 Endothelial dysfunction is an early event in the development of atherosclerosis and flow-mediated dilatation (FMD) of the brachial artery is the non-invasive technique of choice for its assessment. 4, 5 ART, irrespective of the antiretroviral drugs contained in the regimen, has been shown to improve endothelial function in the initial short term in treatment-naive HIV-infected patients. 6 In patients on stable ART, switching from a PI/r-based regimen to boosted/unboosted atazanavir did not demonstrate significant changes in FMD. 7, 8 We evaluated the effect on endothelial function of switching the PI/r component to raltegravir in virologically suppressed HIV-infected patients.
Methods
This is a substudy of the SPIRAL trial that was planned prior to the initiation of the trial. 9 The SPIRAL study was a multicentre, randomized, open-label clinical study including HIV-infected patients who were on a stable PI/r-based antiretroviral regimen and were virologically suppressed for at least the previous 6 months. All from the General University Hospital of Elche, Spain, 9 were invited to participate in this substudy and all of them accepted. Patients were assigned in a 1 : 1 ratio to switch to raltegravir or to continue on the PI/r regimen while maintaining the same background therapy. According to the SPIRAL trial, all patients were assessed at baseline and 4, 16, 32 and 48 weeks. For the purpose of this substudy, an additional visit was planned at week 24. The local Ethics Committee approved the protocol and all the patients gave their informed consent.
At baseline and 4, 16, 32 and 48 weeks, clinical data were collected and blood samples were obtained after ≥8 h overnight fast to measure plasma lipid concentrations. 9 Endothelial function was evaluated by measuring FMD with a high-resolution linear array vascular ultrasound transducer (Nemio XG, Toshiba Medical Systems SA, Madrid, Spain) at baseline and weeks 24 and 48, as previously described. 10 Subjects were required to be fasting and not to use any tobacco-containing products for 8 h before the study. Non-fasting subjects were given a new appointment to have the test performed on a different day. FMD was calculated as the ratio of the brachial artery diameter after reactive hyperaemia to the baseline diameter and was expressed as a percentage of change. Nitroglycerin-mediated vasodilatation was also determined. Measurements were performed by an experienced examiner blinded to the subject's information. Reproducibility was assessed by the same examiner in 10 healthy subjects (8 men, age 44+8.5 years) who had FMD measured twice at an interval of 2 h. Median (IQR) FMD was 8.15% (5.26%-12.1%). The median (IQR) intraobserver intersession percentage of variation for the brachial artery diameter was 2.38% (0%-5.71%), which was within the reported range. 11 Lipodystrophy was defined as the presence of body fat changes that could be clearly recognized by both the patient and the doctor.
All reported values are medians (IQR). The Wilcoxon signed rank test was used to assess within-arm changes in FMD and laboratory tests, and the Mann-Whitney test was used to evaluate between-arm changes. Endothelial function after switching the protease inhibitor to raltegravir 411 
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Results
Between April and December 2009, 37 patients were enrolled: 20 to the raltegravir arm and 17 to remain on their current PI/r. Two patients were excluded from the study within the first month after randomization: one in the raltegravir arm because of serious adverse event development and another patient in the PI/r arm because she became pregnant. The baseline characteristics are shown in Table 1 . Both treatment arms were equally balanced, including baseline plasma lipid concentrations, brachial artery diameter and FMD. The most common PI/r at entry was lopinavir/ritonavir (45.9%), followed by atazanavir/ritonavir (29.7%). No changes in lipid-lowering therapy occurred during the 48 week period.
No significant changes from baseline occurred in FMD at weeks 24 and 48 within or between the raltegravir and PI/r arms ( Table 1) . Baseline brachial artery diameter did not change during the 48 week study period and adjustment for baseline artery diameter did not have a significant effect on the between-arm FMD differences (Table 1) . Power calculation based on 17 patients per group predicted 78.3% power to detect an absolute difference in the change of FMD of 3% (standard deviation 5%) and 90% power to detect an absolute difference in mean FMD of 3.6%. When analysis was restricted to patients not on lipid-lowering therapy (n¼ 15 in each arm), FMD was again not different within (P ¼ 0.97 and P ¼ 0.38 for the raltegravir arm and P ¼ 0.70 and P¼ 0.93 for the PI/r arm at weeks 24 and 48, respectively) or between (P ¼ 0.79 and P ¼ 0.70 at weeks 24 and 48, respectively) the arms.
Compared with baseline levels, total cholesterol, low-density lipoprotein (LDL) cholesterol, non-high-density lipoprotein (non-HDL) cholesterol and triglycerides decreased at weeks 16 and 32 in the raltegravir-switch arm, while no changes were observed in the PI/r arm (Table 1) . At week 48, triglycerides were also significantly lower than at baseline in the raltegravir arm and there was a non-significant trend to lower total cholesterol (P¼ 0.085) and non-HDL cholesterol (P ¼0.076), not observed in the PI/r arm. Triglyceride levels were significantly lower in the raltegravir arm than in the PI/r arm at weeks 16, 32 and 48 (Table 1) . No changes occurred in the total cholesterol/HDL cholesterol ratio within or between groups.
Discussion
Our results suggest that in virologically suppressed patients, switching from a PI/r-containing regimen to raltegravir does not lead to any evident improvement in endothelial function after a 1 year follow-up, in spite of a significant reduction in plasma lipid levels. These results resemble those found in patients changing their PI/r to boosted 7 or unboosted 8 atazanavir. Patients included in our study were on stable ART, with sustained virological suppression, and had median baseline FMD values .5%, a figure that may be considered within normal limits according to results obtained in the general population 11, 12 and similar to values observed in HIV-infected patients after achieving undetectable HIV viral load with diverse antiretroviral regimens. 6 This might have obscured any potential benefits of raltegravir on endothelial function. Additionally, although the arms were well balanced, differences existing between the groups and the low sample size might have precluded us from detecting clinically relevant differences in the FMD change under the value the study was powered for. In contrast, the random assignment of patients is a strength of the study and the sample size allowed us to find differences in the lipid profile, suggesting that if an improvement in endothelial function actually existed, it should probably be of low magnitude. In a much larger sample of patients from this trial, no changes in biomarkers of endothelial activation were observed in patients switching to raltegravir, in spite of a reduction in inflammation and hypercoagulability markers. 13 This may reflect the multifactorial origin of endothelial dysfunction, which has also been found to be partially independent of inflammatory markers in particular scenarios, 14 and that specific antiretrovirals probably have a preferential or at least a detectable action on selected mechanisms implicated in atherogenesis.
We conclude that switching from a PI/r-based antiretroviral regimen to raltegravir in patients with virological suppression has a beneficial impact on the lipid profile, but it does not have a clear impact on endothelial function after a 1 year follow-up. 
